Parecoxib, sold under the brand name Dynastat among others, is a water-soluble and injectable prodrug of valdecoxib. Parecoxib is a COX2 selective inhibitor. It is injectable. It is approved in the European Union for short term perioperative pain control. Chemically, parecoxib sodium is an N-propargyl sulfonamide carbamate derivative formulated for parenteral administration; on administration it is rapidly converted by plasma and hepatic esterases to the active COX2 inhibitor valdecoxib. The formulation is intended for intravenous or intramuscular use and provides analgesia without the need for an oral route in the perioperative setting. Key properties relevant to handling and formulation include good aqueous solubility as the sodium salt, stability under recommended refrigerated storage conditions, and predictable conversion kinetics to valdecoxib allowing rapid onset of analgesic effect. Pharmacologically, the active metabolite selectively reduces prostaglandin synthesis by inhibiting the cyclooxygenase 2 enzyme, producing analgesic and anti-inflammatory effects while minimizing cyclooxygenase 1 related gastrointestinal effects compared with nonselective NSAIDs. Clinical considerations include dosage limits for short term use, renal and hepatic function monitoring as indicated, and caution in patients with known sulfonamide allergy or significant cardiovascular risk.
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
![N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]acetamide](https://veeprho.com/wp-content/uploads/2024/10/VE0021882-N-4-5-Methyl-3-phenyl-4-isoxazolyl.png "N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]acetamide")
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Parent: Parecoxib
Typical impurity and related-compound controls for parecoxib active pharmaceutical ingredient focus on process-related impurities, residual solvents, and degradation products including the primary active metabolite valdecoxib and predictable hydrolysis products. Quality control specifications commonly reference ICH guidelines; reporting thresholds are often set at 0.05 percent for low daily dose APIs, with identification and qualification thresholds applied per ICH Q3A/Q3B. In practice manufacturers limit individual specified related substances to the range of 0.1 to 0.5 percent and the total of all impurities to not exceed about 1.0 percent, with tighter limits applied to known genotoxicants or identified toxicological concerns. Typical monitored impurities include valdecoxib (as a related compound), N-dealkylation and hydrolysis products, trace process reagents and byproducts, and any oxidative or photolytic degradants; acceptance criteria and analytical methods such as HPLC with validated impurity profiling are used to ensure batch-to-batch control.
Parecoxib is used for short term management of moderate to severe postoperative pain in adults where an injectable COX2 selective analgesic is desirable, typically administered perioperatively as part of a multimodal analgesic regimen to reduce opioid requirements.
No, Parecoxib is a parenteral prodrug that is converted to valdecoxib and is a COX2 selective inhibitor for injectable use. Celebrex is the brand name for celecoxib, an oral COX2 selective inhibitor with a different chemical structure and pharmacokinetic profile. They belong to the same pharmacologic class but are distinct compounds with different routes of administration and regulatory approvals.
Parecoxib and tramadol are different classes of analgesics and are not directly interchangeable. Parecoxib is a COX2 selective nonsteroidal anti-inflammatory prodrug providing anti-inflammatory and analgesic effects and may reduce opioid needs. Tramadol is a centrally acting analgesic with mu opioid receptor activity and monoaminergic effects. Choice depends on pain type, contraindications, side effect profiles and clinical goals; in some settings combining agents or using one agent over the other is preferred based on efficacy, safety and patient factors rather than an absolute superiority.
Parecoxib itself is inactive and is rapidly hydrolyzed by plasma and hepatic esterases to the active metabolite valdecoxib, which selectively and reversibly inhibits the cyclooxygenase 2 enzyme, reducing prostaglandin synthesis at sites of inflammation and injury and thereby producing analgesic and anti-inflammatory effects.
